MedTrace Logo

Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

NCT00971334 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2502

Last updated 2012-02-17

No results posted yet for this study

Summary

The purpose of this study is to collect samples for the purpose of developing a prenatal aneuploid test using circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have a high-risk pregnancy undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploid test will be compared to the chromosomal analysis obtained via CVS or amniocentesis.

Conditions

  • Pregnancy
  • Aneuploidy
  • Down Syndrome
  • Edwards Syndrome

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Allan T Bombard, MD · Sequenom, Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00971334 on ClinicalTrials.gov